Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants.
| dc.rights.license | open | en_US |
| dc.contributor.author | KAMINSKI, Hanah | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | COUZI, Lionel | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | GARRIGUE, Isabelle
IDREF: 12258953X | |
| dc.contributor.author | MOREAU, J-F | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | DECHANET-MERVILLE, Julie
IDREF: 061667994 | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | MERVILLE, Pierre | |
| dc.date.accessioned | 2023-11-17T17:24:38Z | |
| dc.date.available | 2023-11-17T17:24:38Z | |
| dc.date.issued | 2016-08-01 | |
| dc.identifier.issn | 1600-6143 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/184831 | |
| dc.description.abstractEn | Universal prophylaxis for cytomegalovirus (CMV) prevention is viable but, compared with a preemptive strategy, leads to higher incidence of late-onset disease (LOD) associated with poor patient and graft survival. The purpose of this study was to compare LOD with early onset disease (EOD), with a focus on the highest risk kidney transplant recipients (KTRs): CMV seronegative recipients transplanted from seropositive donors (D+R-). Since CMV control depends on both antiviral treatment and specific immune response, we also compared Vδ2-negative (Vδ2(neg) ) γδ T cell expansion involved in CMV infection resolution. EOD was defined as occurring 3 mo after transplantation. Depending on the period, universal prophylaxis or preemptive treatment was used. Overall, 168 D+R- KTRs were included between 2003 and 2011. LOD was associated with a lower peak DNAemia (p = 0.04), fewer recurrences (odds ratio 0.16; 95% confidence interval 0.05-0.55; p = 0.01) and shorter anti-CMV curative treatment (40 vs. 60 days, p < 0.0001). As a corollary, we found that Vδ2(neg) γδ T cell expansion was faster in LOD than in EOD (31 vs. 168 days after the beginning of CMV disease, p < 0.0001). In D+R- KTRs, universal prophylaxis is associated with more LOD, which had better infection management and a faster immune response. These results support the use of universal prophylaxis over a preemptive strategy and reappraise outcomes of LOD. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Age of Onset | |
| dc.subject.en | Antiviral Agents | |
| dc.subject.en | Cytomegalovirus | |
| dc.subject.en | Cytomegalovirus Infections | |
| dc.subject.en | Female | |
| dc.subject.en | Follow-Up Studies | |
| dc.subject.en | Glomerular Filtration Rate | |
| dc.subject.en | Graft Survival | |
| dc.subject.en | Humans | |
| dc.subject.en | Kidney Failure | |
| dc.subject.en | Chronic | |
| dc.subject.en | Kidney Function Tests | |
| dc.subject.en | Kidney Transplantation | |
| dc.subject.en | Male | |
| dc.subject.en | Middle Aged | |
| dc.subject.en | Prognosis | |
| dc.subject.en | Retrospective Studies | |
| dc.subject.en | Risk Factors | |
| dc.subject.en | T-Lymphocytes | |
| dc.subject.en | Tissue Donors | |
| dc.title.en | Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants. | |
| dc.title.alternative | Am J Transplant | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/ajt.13781 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Microbiologie et Parasitologie | en_US |
| dc.identifier.pubmed | 26953216 | en_US |
| bordeaux.journal | American Journal of Transplantation | en_US |
| bordeaux.page | 2384-94 | en_US |
| bordeaux.volume | 16 | en_US |
| bordeaux.hal.laboratories | MFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234 | en_US |
| bordeaux.issue | 8 | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04292714 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-11-17T17:24:41Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=American%20Journal%20of%20Transplantation&rft.date=2016-08-01&rft.volume=16&rft.issue=8&rft.spage=2384-94&rft.epage=2384-94&rft.eissn=1600-6143&rft.issn=1600-6143&rft.au=KAMINSKI,%20Hanah&COUZI,%20Lionel&GARRIGUE,%20Isabelle&MOREAU,%20J-F&DECHANET-MERVILLE,%20Julie&rft.genre=article |
